INTUITIVE SURGICAL Business Summary

Intuitive Surgical Inc. (ISRG) utilizes a high-margin "razor-and-blade" business model to dominate the robotic-assisted surgery (RAS) market, generating $10.06 billion in FY 2025 revenue. The company’s financial structure is divided into three primary segments: Instruments and Accessories (59.8% of revenue), which provides high-margin recurring income from procedure-specific tools; Systems (24.6%), comprising capital sales of the da Vinci 5, X, Xi, and Ion platforms; and Services (15.6%), covering maintenance and training. With a global installed base exceeding 10,000 systems and a projected 2026 procedure growth of 13-15%, Intuitive maintains a wide economic moat through its integrated digital ecosystem and extensive clinical validation. It remains the preeminent market leader, successfully maintaining its position against direct competitors such as Medtronic (Hugo), Stryker (MAKO), and Johnson & Johnson (Ottava) by leveraging superior surgeon training networks and a robust pipeline of AI-driven diagnostic tools. Founded in 1995 by Frederic Moll, John Freund, and Robert Younge, Intuitive is currently led by CEO David J. Rosa, a 30-year veteran and the company’s ninth employee who assumed the role in July 2025. He is supported by Executive Chair Gary S. Guthart, the former long-time CEO, and CFO Jamie E. Samath. The technical leadership includes Christopher Carlson, EVP of Research, and Brian E. Miller, who transitioned to Head of Digital and AI Strategy in January 2026 to spearhead the company’s machine learning initiatives. The company’s governance is overseen by a board featuring Lead Independent Director Craig H. Barratt (former CEO of Atheros) and notable directors like Sreelakshmi Kolli and Amal Johnson. Major institutional backing is provided by The Vanguard Group and BlackRock, which collectively hold nearly 20% of the company’s equity, reflecting its status as a core holding in the healthcare technology sector.